Trial · NCT03984188
Adverse events20
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 20
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | COPD Exacerbation | Respiratory, thoracic and mediastinal disorders | Low-dose Theophylline Group | 14 | 50 | |
| other | COPD Exacerbation | Respiratory, thoracic and mediastinal disorders | Placebo Group | 10 | 49 | |
| other | Arthalgia/Myalgia | Musculoskeletal and connective tissue disorders | Low-dose Theophylline Group | 3 | 50 | |
| other | Arthalgia/Myalgia | Musculoskeletal and connective tissue disorders | Placebo Group | 5 | 49 | |
| other | Change in urinary frequency | Renal and urinary disorders | Low-dose Theophylline Group | 2 | 50 | |
| other | Change in urinary frequency | Renal and urinary disorders | Placebo Group | 0 | 49 | |
| other | Gastritis | Gastrointestinal disorders | Low-dose Theophylline Group | 7 | 50 | |
| other | Gastritis | Gastrointestinal disorders | Placebo Group | 4 | 49 | |
| other | Insomnia | Psychiatric disorders | Low-dose Theophylline Group | 0 | 50 | |
| other | Insomnia | Psychiatric disorders | Placebo Group | 1 | 49 | |
| serious | Hospitalization for Respiratory Failure | Respiratory, thoracic and mediastinal disorders | Low-dose Theophylline Group | 3 | 50 | 3 |
| serious | Hospitalization for Respiratory Failure | Respiratory, thoracic and mediastinal disorders | Placebo Group | 2 | 49 | 2 |
| serious | Hospitalization for Stroke | Nervous system disorders | Low-dose Theophylline Group | 1 | 50 | 1 |
| serious | Hospitalization for Stroke | Nervous system disorders | Placebo Group | 0 | 49 | 0 |
| serious | Renal Failure | Renal and urinary disorders | Low-dose Theophylline Group | 0 | 50 | 0 |
| serious | Renal Failure | Renal and urinary disorders | Placebo Group | 1 | 49 | 1 |
| serious | Hospitalization for anemia | Blood and lymphatic system disorders | Low-dose Theophylline Group | 0 | 50 | 0 |
| serious | Hospitalization for anemia | Blood and lymphatic system disorders | Placebo Group | 1 | 49 | 1 |
| serious | Hospitalization for failure to thrive | General disorders | Low-dose Theophylline Group | 1 | 50 | 1 |
| serious | Hospitalization for failure to thrive | General disorders | Placebo Group | 0 | 49 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03984188/events